Cancer immunotherapy

Forty Seven Inc. to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

Retrieved on: 
Tuesday, November 5, 2019
Cancer immunotherapy

ET (5:00 a.m. PT) on Tuesday, November 12, 2019 to report its third quarter 2019 financial results and provide a corporate update.

Key Points: 
  • ET (5:00 a.m. PT) on Tuesday, November 12, 2019 to report its third quarter 2019 financial results and provide a corporate update.
  • The live call may be accessed by dialing (866) 953-0780 for domestic callers or (630) 652-5854 for international callers and providing the conference ID number 7667736.
  • An audio webcast of the call will also be available under Events & Presentations in the Investors section of Forty Sevens website at www.fortyseveninc.com .
  • Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University.

WindMIL Therapeutics to Present Data Demonstrating Marrow-Infiltrating Lymphocytes’ (MILs™) Superior Functionality Compared to Peripheral Blood Counterparts at 34th Annual Meeting of the Society for Immunotherapy of Cancer

Retrieved on: 
Tuesday, November 5, 2019
Medical specialties, Animal anatomy, Lymphatic system, Stem cells, Bone marrow, Hematopoiesis, Skeletal system, Cancer immunotherapy, Lymphocyte, Immunotherapy, Immunology

Based on these data and the inherent antitumor properties of MILs, we believe CAR-MILs could be more potent and effective than currently approved CAR-T products derived from peripheral blood lymphocytes, said Eric Lutz, Ph.D., director of research at WindMIL Therapeutics.

Key Points: 
  • Based on these data and the inherent antitumor properties of MILs, we believe CAR-MILs could be more potent and effective than currently approved CAR-T products derived from peripheral blood lymphocytes, said Eric Lutz, Ph.D., director of research at WindMIL Therapeutics.
  • WindMIL is developing both unmodified and gene-modified forms of MILs.
  • Details of the poster presentation are as follows:
    WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow infiltrating lymphocytes (MILs) for cancer immunotherapy.
  • As the leader in cellular therapeutics emanating from bone marrow, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients.

HOOKIPA Pharma To Report Third Quarter 2019 Financial Results on November 12, 2019

Retrieved on: 
Monday, November 4, 2019
Cancer immunotherapy, Antigen, Medicine, Biology

NEW YORK and VIENNA, Austria, Nov. 04, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, will announce financial results for the third quarter ended September 30, 2019 on Tuesday, November 12, 2019, after the NASDAQ market close.

Key Points: 
  • NEW YORK and VIENNA, Austria, Nov. 04, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, will announce financial results for the third quarter ended September 30, 2019 on Tuesday, November 12, 2019, after the NASDAQ market close.
  • Until otherwise noted, the Company will only conduct an earnings conference call in conjunction with its fourth quarter earnings releases.
  • HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.
  • TheraT and VaxWave are not approved anywhere globally and their safety and efficacy have not been established.

NeoTX Therapeutics to Present at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

Retrieved on: 
Monday, November 4, 2019
Medicine, Clinical medicine, Cancer treatments, Health, Immune system, RTT, Cancer immunotherapy, Immunotherapy, Checkpoint inhibitor, Cancer

REHOVOT, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) -- NeoTX Therapeutics, Ltd. today announced a presentation on the companys lead candidate from its Selective T cell Redirection (STR) platform, naptumomab estafenatox (Nap), at the Society for Immunotherapy of Cancers (SITC) 34th Annual Meeting being held November 6-10, 2019 in National Harbor, Maryland.

Key Points: 
  • REHOVOT, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) -- NeoTX Therapeutics, Ltd. today announced a presentation on the companys lead candidate from its Selective T cell Redirection (STR) platform, naptumomab estafenatox (Nap), at the Society for Immunotherapy of Cancers (SITC) 34th Annual Meeting being held November 6-10, 2019 in National Harbor, Maryland.
  • The poster presentation will highlight preclinical data demonstrating that Nap and checkpoint inhibitors work synergistically to induce a prolonged and protective immune response against solid tumors.
  • Details on the presentation are as follows:
    Session Date & Time: Friday, November 8, 2019, 12:30 2:00 p.m. and 6:30 8:00 p.m. EST

Agenus Provides Corporate Update with Third Quarter 2019 Financial Results

Retrieved on: 
Monday, November 4, 2019
Agenus, Cancer immunotherapy, Companies, Biotechnology

LEXINGTON, Mass., Nov. 4, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vaccines provided a corporate update and reported financial results for the third quarter of 2019.

Key Points: 
  • LEXINGTON, Mass., Nov. 4, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vaccines provided a corporate update and reported financial results for the third quarter of 2019.
  • 2020 is expected to be an important year of data generation, substantial milestone payments and prudent collaborations for Agenus.
  • Cash used in operations for the quarter ended September 2019 was $28 million compared to $25 million for the same period in 2018.
  • Through the third quarter of 2019 we also recorded $30 million of non-cash interest expense due to our transaction with HCR related to the sale of future royalties.

Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting

Retrieved on: 
Friday, November 1, 2019
RTT, Health, Medical specialties, Medicine, Melanoma, Nektar Therapeutics, Cancer immunotherapy, SITC, Society for Immunotherapy of Cancer, Cancer, Nektar

SAN FRANCISCO, Nov. 1, 2019 /PRNewswire/ --Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with a melanoma specialist and company management on Sunday, November 10, 2019 at 9:00 a.m. EST in Washington, D.C. during the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • SAN FRANCISCO, Nov. 1, 2019 /PRNewswire/ --Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with a melanoma specialist and company management on Sunday, November 10, 2019 at 9:00 a.m. EST in Washington, D.C. during the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
  • The call will be hosted by Nektar management and will also include Dr. Adi Diab, Assistant Professor, Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center.
  • Date: Sunday, November 10th at 9:00 a.m. Eastern Standard Time
    Investors and analysts can also view slides and listen to the live audio webcast of the presentation at https://edge.media-server.com/mmc/p/jirxdbd4 .
  • Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com .

Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019

Retrieved on: 
Friday, November 1, 2019
Articles, Life sciences, Health sciences, Cancer immunotherapy, Therapy, Cancer, Biopharmaceutical

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Third Quarter 2019 and provide a business update, before the U.S. markets open on Wednesday, November 6, 2019.

Key Points: 
  • PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Third Quarter 2019 and provide a business update, before the U.S. markets open on Wednesday, November 6, 2019.
  • The press release and the live webcast of the conference call will be available in the investor section of Adaptimmunes corporate website at www.adaptimmune.com .
  • After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (3997944).
  • Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients.

Checkmate Pharmaceuticals Announces Data Presentations for Lead Program at The 34th Annual Meeting of The Society for Immunotherapy of Cancer

Retrieved on: 
Friday, November 1, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medicine, Medical specialties, Clinical medicine, Cancer treatments, TLR9, Cancer immunotherapy, Society for Immunotherapy of Cancer, Immunotherapy, SITC, CMP-001, Checkmate Pharmaceuticals

Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer, today announced two oral presentations at The 34th Annual Meeting of The Society for Immunotherapy of Cancer (SITC).

Key Points: 
  • Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer, today announced two oral presentations at The 34th Annual Meeting of The Society for Immunotherapy of Cancer (SITC).
  • CMP001 is a firstinclass CpGA Tolllike receptor 9 (TLR9) agonist that is encapsulated in a viruslike particle.
  • CMP001 is being evaluated in multiple tumor types to assess safety, activity, alternative routes of administration and combination with other immunotherapies and modalities.
  • Checkmates lead product candidate, CMP-001, is an investigational cancer immunotherapeutic that has been shown to reverse resistance to PD-1 therapy in some patients.

Replimune to Host Investor Event at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Thursday, October 31, 2019
Experimental cancer treatments, Virotherapy, Medicine, Biotechnology, Cancer immunotherapy, Oncolytic virus, Clinical medicine, Treatment of cancer, Life sciences

The presentation will focus on the data being presented at SITC as well as additional supporting data from the clinical trial.

Key Points: 
  • The presentation will focus on the data being presented at SITC as well as additional supporting data from the clinical trial.
  • The presentation will begin at 6:30 p.m. Eastern Time on Friday, November 8, 2019 in National Harbor, MD.
  • Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer.
  • Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action.For more information, please visit www.replimune.com .

Eureka Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Retrieved on: 
Thursday, October 31, 2019
Oncology, Health, Clinical trials, Research, Science, Biotechnology, Medical specialties, Medicine, Branches of biology, Immune system, Hepatology, Single-pass transmembrane proteins, Immunology, Cancer immunotherapy, T-cell receptor, Hepatocellular carcinoma, Liver cancer, T cell

Eureka Therapeutics, Inc ., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, today announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, November 6-10, 2019, in National Harbor, Maryland.

Key Points: 
  • Eureka Therapeutics, Inc ., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, today announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, November 6-10, 2019, in National Harbor, Maryland.
  • The presentation will highlight the companys proprietary ARTEMIS antibody T-cell receptor (AbTCR) platform used to develop ET140202 for the treatment of hepatocellular carcinoma (HCC), the most predominant type of liver cancer.
  • ET140202 features ARTEMIS T-cell receptors engineered with a TCR-mimic antibody to target the alpha-fetoprotein (AFP) peptide/ major histocompatibility complex (MHC) on HCC cancer cells.